Royce & Associates LP Trims Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Royce & Associates LP lessened its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 47.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,402 shares of the company’s stock after selling 42,020 shares during the quarter. Royce & Associates LP owned approximately 0.13% of RxSight worth $2,343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its stake in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after buying an additional 371 shares during the period. Nisa Investment Advisors LLC raised its holdings in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock valued at $29,000 after acquiring an additional 521 shares during the last quarter. Quest Partners LLC purchased a new position in shares of RxSight during the 2nd quarter worth $41,000. Amalgamated Bank boosted its holdings in shares of RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares during the last quarter. Finally, KBC Group NV grew its position in shares of RxSight by 63.6% in the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after purchasing an additional 479 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

Insider Buying and Selling at RxSight

In related news, insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,225,096.82. This trade represents a 6.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jesse Anderson Corley purchased 11,111 shares of RxSight stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the transaction, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. This represents a 2.43 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 52,720 shares of company stock valued at $2,603,950 over the last three months. 9.36% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Wells Fargo & Company decreased their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus lowered their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group assumed coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Finally, Oppenheimer cut their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight currently has an average rating of “Buy” and a consensus target price of $61.63.

RxSight Trading Up 1.0 %

NASDAQ:RXST opened at $45.12 on Wednesday. The firm’s fifty day simple moving average is $49.97 and its 200 day simple moving average is $53.04. RxSight, Inc. has a twelve month low of $27.07 and a twelve month high of $66.54. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -54.36 and a beta of 1.19.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.